Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guohong Han

Showing results (161-170 of 200) with videos related to

Pageof 20
Sort By:
Therapeutic Advances in Medical Oncology|December 20, 2019
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinomaShukui Qin, Stephen Lam Chan, Wattana Sukeepaisarnjaroen, et al.
Cardiovascular and Interventional Radiology|August 2, 2023
Outcome of Children with Transjugular Intrahepatic Portosystemic Shunt: A Meta-Analysis of Individual Patient DataSinan Deniz, Regina Schinner, Eric J Monroe, et al.
Hepatology (Baltimore, Md.)|July 5, 2014
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trialMasatoshi Kudo, Guohong Han, Richard S Finn, et al.
Hepatology (Baltimore, Md.)|April 16, 2016
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaAnn-Lii Cheng, Sumitra Thongprasert, Ho Yeong Lim, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 2, 2018
Association between non-variceal spontaneous portosystemic shunt and outcomes after TIPS in cirrhosisChuangye He, Yong Lv, Zhengyu Wang, et al.
Lancet (London, England)|February 14, 2018
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialMasatoshi Kudo, Richard S Finn, Shukui Qin, et al.
Alimentary Pharmacology & Therapeutics|March 2, 2019
TIPSS for variceal bleeding in patients with idiopathic non-cirrhotic portal hypertension: comparison with patients who have cirrhosisYong Lv, Kai Li, Chuangye He, et al.
Journal of Hepatology|May 17, 2017
Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleedingQiuhe Wang, Yong Lv, Ming Bai, et al.
Liver Cancer|June 30, 2025
Transarterial Chemoembolization plus Sorafenib versus Sorafenib Alone in Advanced Hepatocellular Carcinoma (SELECT): A Multicenter, Phase 3, Randomized, Controlled TrialYan Zhao, Wei Bai, Rong Ding, et al.
Investigational New Drugs|July 19, 2018
Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCCEnxin Wang, Dongdong Xia, Wei Bai, et al.
Pageof 20

Showing results (161-170 of 200) with videos related to

Sort By:
Pageof 20
Therapeutic Advances in Medical Oncology|December 20, 2019
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinomaShukui Qin, Stephen Lam Chan, Wattana Sukeepaisarnjaroen, et al.
Cardiovascular and Interventional Radiology|August 2, 2023
Outcome of Children with Transjugular Intrahepatic Portosystemic Shunt: A Meta-Analysis of Individual Patient DataSinan Deniz, Regina Schinner, Eric J Monroe, et al.
Hepatology (Baltimore, Md.)|July 5, 2014
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trialMasatoshi Kudo, Guohong Han, Richard S Finn, et al.
Hepatology (Baltimore, Md.)|April 16, 2016
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaAnn-Lii Cheng, Sumitra Thongprasert, Ho Yeong Lim, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 2, 2018
Association between non-variceal spontaneous portosystemic shunt and outcomes after TIPS in cirrhosisChuangye He, Yong Lv, Zhengyu Wang, et al.
Lancet (London, England)|February 14, 2018
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialMasatoshi Kudo, Richard S Finn, Shukui Qin, et al.
Alimentary Pharmacology & Therapeutics|March 2, 2019
TIPSS for variceal bleeding in patients with idiopathic non-cirrhotic portal hypertension: comparison with patients who have cirrhosisYong Lv, Kai Li, Chuangye He, et al.
Journal of Hepatology|May 17, 2017
Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleedingQiuhe Wang, Yong Lv, Ming Bai, et al.
Liver Cancer|June 30, 2025
Transarterial Chemoembolization plus Sorafenib versus Sorafenib Alone in Advanced Hepatocellular Carcinoma (SELECT): A Multicenter, Phase 3, Randomized, Controlled TrialYan Zhao, Wei Bai, Rong Ding, et al.
Investigational New Drugs|July 19, 2018
Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCCEnxin Wang, Dongdong Xia, Wei Bai, et al.
Pageof 20